Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XIRIUS: BIIB112 Gene Therapy for XLRP
NCT03116113Phase 2Completed
- Sponsor
- Biogen
- Start
- Mar 2017
- Primary completion
- Nov 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of cotoretigene toliparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by Biogen. Started Mar 2017; status: completed.
02
Drugs
cotoretigene toliparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT03116113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116113.